A Single-Institution Review of Portosystemic Shunts in Children: An Ongoing Discussion

Table 1

Ten patients were identified in the study. They are listed from 1 to 10 and referenced this way throughout the paper. DSRS: distal splenorenal shunt; PSRS: proximal splenorenal shunt; PCS: portocaval shunt; PV: portal vein; UTI: urinary tract infection. *MELD score 1 month post shunt. **MELD score 1 month and 13 years post shunt.

Patient no.	Age	Primary disease	Shunt type	MELD/PELD score pre- and postop		Primary reason for shunt	Complications	30-day mortality	Graft patency	Followup years
EHPH group
1	17	PV Thrombosis	DSRS			Variceal Bleeding	None	None	Patent	7.08 Alive
2	17	PV Thrombosis	PSRS			Variceal Bleeding	None	None	Thrombosed	1.08 Alive
IHPH group
3	17	Congenital Hepatic Fibrosis	DSRS	6	6	Variceal Bleeding	None	None	Patent	7.4 Alive
4	5	Congenital Hepatic Fibrosis	Side-to-side PCS	7	8	Variceal Bleeding	UTI, central-line infection	None	Patent	0.92 Alive
5	19	Cystic Fibrosis	DSRS	7	11	Variceal Bleeding	None	None	Patent	0.5 Died
6	15	Congenital Hepatic Fibrosis	PSRS	20	21	Variceal Bleeding	Bleeding Fundal Varices 10 days postop	Negative reexploration	Received liver transplant 13 months later post PSS	1.08 Alive
7	18	Hepatic Vein Thrombosis	Side-to-side PCS	18	12*	Liver Dysfunction	None	None	Shunt occluded at 3 months. Received liver txp 6 months later	12.8 Died
8	18	Hepatic Vein Thrombosis	PCSH-graft	18	13**	Liver Dysfunction	None	None	Patent	13.16 Alive
9	15	Congenital Hepatic Fibrosis	DSRS	7	7	Hypersplenism	None	None	Patent	6.5 Alive
10	10	Congenital Hepatic Fibrosis	Side-to-side PCS	8	11	Hypersplenism	None	None	Patent	1.92 Alive